Ascent Trial News Today

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Kevin Kalinsky, MD, MS, discusses genetic sequencing in triple-negative breast cancer, the significance of breast cancer tumor board discussions for informing further research and optimizing patient care, and how future directions in breast cancer treatment are building off the current benefits of drugs classes like antibody-drug conjugates.